Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese
patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in
Japanese pts. with relapsed or refractory CTCL. Relapsed or refractory CTCL patients will be
newly enrolled in Part II.